An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Olaratumab (Primary) ; Pembrolizumab (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Eli Lilly
- 19 Feb 2018 Planned End Date changed from 1 Jun 2020 to 1 Oct 2020.
- 19 Feb 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Oct 2019.
- 20 Oct 2017 Planned End Date changed from 13 Feb 2020 to 1 Jun 2020.